PYC stated on two separate occasions, (within two comprehensive & information rich updates, both of which were price sensitive ASX announcements), that an application to the FDA for approval to commence in-human trials targeting PKD would be submitted in late December of 2024, (albeit, late in December 2024).
I think PYC have therefore satisfactorily informed the market on that basis. In contrast, I would be pretty darn sure that PYC would be required to provide a formal update if there was a material delay rather than announcing again what has already been adequately communicated.
The next step in regard to this matter, would be a response from the FDA, which may possibly arrive in the fairly near future. Approximately early February methinks?
I am holding tight, just wish I had enough moolah to buy a few more at around current pricing. (this is not meant as advise, each to their own circumstances)
PYC Price at posting:
$1.22 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)